Popular terms

[SEARCH]

Immune Diseases topics
Immune Diseases
Autoimmune
Immune Disease
Autoimmune Disease
Autoimmune Diseases
Immune Disorder
Rheumatoid Arthritis
Antibodies
Antagonist
Nucleotide
Proliferative
Infectious
Infectious Disease
Infectious Diseases
Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Diseases patents



      
           
This page is updated frequently with new Immune Diseases-related patent applications. Subscribe to the Immune Diseases RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Diseases RSS RSS



Date/App# patent app List of recent Immune Diseases-related patents
07/30/15
20150210704 
 Inhibitors of bruton's tyrosine kinase patent thumbnailnew patent Inhibitors of bruton's tyrosine kinase
This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


07/30/15
20150210703 
 Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases patent thumbnailnew patent Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof. The formula i compounds inhibit tyrosine kinase activity of jak3, thereby making them useful for the treatment of inflammatory and autoimmune diseases..
Bristol-myers Squibb Company


07/30/15
20150209288 
 Core-shell particle formulation for delivering multiple therapeutic agents patent thumbnailnew patent Core-shell particle formulation for delivering multiple therapeutic agents
A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, the formulation comprising protein-protein core-shell particle configured to independently release therapeutic agents from the core and the shell.
Amrita Vishwa Vidyapeetham


07/23/15
20150203847 
 Chemical modifications of monomers and oligonucleotides with cycloaddition patent thumbnailChemical modifications of monomers and oligonucleotides with cycloaddition
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

07/23/15
20150203560 
 Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases patent thumbnailEngineered antibody-interferon fusion molecules for treatment of autoimmune diseases
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (ifn) molecule attached to an antibody (ab) which targets an antigen which is differentially expressed or up-regulated on activated t cells as compared to resting t cells, wherein the fusion molecule when contacted to an activated t cell results in induced apoptosis and programmed cell death or impairment of functions of said activated t cell..
Immungene Inc.


07/23/15
20150203455 
 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailNovel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202318 
 Aberrant cell-restricted immunoglobulins provided with a toxic moiety patent thumbnailAberrant cell-restricted immunoglobulins provided with a toxic moiety
Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.


07/23/15
20150202285 
 Compositions and methods for modulating immune responses patent thumbnailCompositions and methods for modulating immune responses
This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the nf-κb signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases..
The University Of Queensland


07/16/15
20150196511 
 Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease patent thumbnailComposition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease
The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of il-17 and tnf-a, and promoting or increasing the activity of ifnr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease..
Catholic University Industry Academic Cooperation Foundation


07/09/15
20150191699 
 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof patent thumbnailMesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
Imstem Biotechnology, Inc.


07/09/15
20150191464 

Heteroaryl substituted nicotinamide compounds


Or salts thereof, wherein: het is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1h-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with ra and rb; and r1 and r2 are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.

07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/02/15
20150183775 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


07/02/15
20150182539 

Pregnancy hormone combination for treatment of autoimmune diseases


The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.. .
The Regents Of The University Of California


07/02/15
20150182487 

Composition for preventing and treating inflammatory diseases and immune diseases, containing apo-9`-fucoxanthinone as active ingredient


The present invention relates to a composition for preventing and treating inflammatory diseases and immune diseases, containing a sargassum muticum extract and apo-9′-fucoxanthinone as active ingredients. According to the present invention, the sargassum muticum extract and apo-9′-fucoxanthinone show an excellent inhibiting activity for the generation of il-12, il-6 and tnf-α, which are inflammatory cytokines, in a macrophage and a dendritic cell due to a stimulating factor causing an inflammatory response, remarkably inhibit mapk and ap-1 activity, and inhibit the activity of nlrp3 inflammasome which is known to be involved in the pathogenesis of various immune inflammatory diseases, and thus can be ultimately useful for the development of an agent for treating inflammatory diseases and immune diseases caused by an excessive immune inflammatory response.
Jeju National University Industry Academic Cooperation Foundation


06/25/15
20150175979 

Ptprs and proteoglycans in autoimmune disease


Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology


06/25/15
20150175710 

Alpha-enolase specific antibodies and use in immune diseases


A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology


06/25/15
20150175623 

Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them


Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .

06/25/15
20150174178 

Method and system for prevention and treatment of allergic and inflammatory diseases


A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

06/18/15
20150166658 

Bcr-complex-specific antibodies and methods of using same


This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


06/18/15
20150165006 

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen


The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Cure Gmbh


06/18/15
20150164948 

Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases


This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services


06/18/15
20150164902 

Concentrated methotrexate solutions


Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh


06/11/15
20150158912 

Treatment of il-17 mediated disease by blocking sefir-sefir interactions


A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.
The Cleveland Clinic Foundation


06/11/15
20150158871 

Crystalline forms of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics, Inc.


06/11/15
20150158865 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics, Inc.


06/04/15
20150152097 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/04/15
20150150951 

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity


The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.

06/04/15
20150150912 

Ceacam1 mediated protective immunity


The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..

05/28/15
20150148361 

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv


05/21/15
20150141523 

Compounds for use in the treatment of autoimmune inflammatory disease


And salts thereof is useful in the prophylaxis or treatment of inflammatory bowel disease or other inflammatory autoimmune diseases with similar aetiology involving t-cell proliferation or or function.. .

05/21/15
20150141397 

Substituted anilines as ccr(4) antagonists


Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.


05/21/15
20150141328 

Stimulation of human meibomian gland function


Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a pld-inducing compound, such as the cationic amphiphilic drugs (e.g. Azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, igf-1 or an igf-1 analogue (e.g.
The Schepens Eye Research Institute


05/21/15
20150140085 

Formulations comprising ibrutinib


Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.. .
Principia Biopharma Inc.


05/14/15
20150132788 

Establishing the viability of biological samples


The invention relates to a method, a use and a kit for establishing the viability (ability to live) of biological samples using ageladine a. The invention is advantageously suitable for establishing the viability of biological samples which can otherwise be dyed in an intra-cellular manner by fluorescence dyes other than ageladine a not at all or only with difficulty.

05/14/15
20150132369 

Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof


A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as cyclosporine a, and the method of preparing the same. The reduced toxicity and significant reduction of delayed-type hypersensitivity dth) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention..

05/14/15
20150132326 

Immunosuppressive blood cells and methods of producing the same


The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .

05/14/15
20150132312 

Systems and methods for extracorporeal blood modification


The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject.

05/07/15
20150125880 

Methods for induction of antigen-specific regulatory t cells


The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory t cells in vitro or in vivo.
Katholieke Universiteit Leuven


05/07/15
20150125536 

Methods and compositions for sustained immunotherapy


This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of tr1 cells and/or breg cells in an antigen-specific manner and treating autoimmune diseases and disorders in a subject in need thereof.. .
Uti Limited Partnership


05/07/15
20150125460 

Anti-bcma antibodies


This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Idec Ma Inc.


05/07/15
20150125390 

18f-labelled folate/antifolate analogues


The present invention is directed towards new 18f-folate/antifolate analogue radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by an 18f-heterocycle, their precursors, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie


04/30/15
20150118318 

Methods of treating inflammatory and autoimmune diseases and disorders


Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Yale University


04/30/15
20150118266 

Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients


The present invention provides a composition for preventing, improving, or treating th1-mediated immune diseases or th2-mediated immune diseases, an antihistamine composition, and an anti-inflammatory composition. The present invention provides a method for preventing, improving, or treating th1-mediated immune diseases or th2-mediated immune diseases, a method for inhibiting the release of histamine, and a method for preventing, improving, or treating inflammatory disorders.
Korea Food Research Institute


04/30/15
20150118264 

Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen


The present invention is directed to a pharmaceutical composition including (e.g. For use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh


04/30/15
20150118259 

28 kda gst proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a th1 and/or th17 response


The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kda glutathione s-transferase protein from a schistosome selected from schistosoma haematobium, schistosoma mansoni, schistosoma bovis represented respectively by the sequences seq id no: 1, seq id no: 2 and seq id no: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type th1 and/or th17.. .
Centre Hospitalier Regional Universitaire De Lille


04/30/15
20150118183 

Negatively charged nucleic acid comprising complexes for immunostimulation


The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. Peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh


04/23/15
20150111873 

Pharmaceutically active pyrazolo-triazine derivatives


Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh


04/23/15
20150111872 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .

04/23/15
20150111835 

Modified peptides and their use for treating autoimmune diseases


The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Centre National De La Rechereche Scientifique


04/23/15
20150110805 

Therapeutic strategy for treating autoimmune and degenerative diseases


Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases.
Immunaid Pty Ltd.


04/16/15
20150104866 

Ip-10 antibodies and their uses


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.




Popular terms: [SEARCH]

Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3411

5390

1 - 1 - 102